Capivasertib is an oral selective pan-AKT inhibitor, which serves as a novel treatment option in advanced breast or prostate cancer in patients with PI3KCA, PTEN, or AKT1 alterations (Andrikopoulou et al. 2022; Luboff et al. 2024; Rugo et al. 2023). This evidence concerns the gene AKT1 and prostate cancer.